Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.44 |
| ▸ | PPARA | Q07869 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5134565 | 0.93 | PPARG (0.42) | PPARGPPARAGAAHPGDSMN1; SMN2 | |
| SCHEMBL5072389 | 0.92 | TSHR (0.41) | PPARGPPARAHPGDTSHRC5AR1 | |
| SCHEMBL5135801 | 0.91 | PPARG (0.45) | PPARGPPARAMEN1KMT2AGAA | |
| SCHEMBL5072207 | 0.91 | PPARG (0.39) | PPARGPPARATSHRC5AR1HSD11B1 | |
| SCHEMBL5137298 | 0.91 | PPARG (0.39) | PPARGPPARANPBWR1TSHRMAPT | |
| SCHEMBL5136818 | 0.91 | PPARG (0.41) | PPARGPPARAMEN1KMT2AGAA | |
| SCHEMBL5135150 | 0.90 | HSD11B1 (0.40) | PPARGPPARATSHRC5AR1HSD11B1 | |
| SCHEMBL5137554 | 0.89 | MAPT (0.38) | PPARGPPARASMN1; SMN2TSHRMAPT | |
| SCHEMBL14415595 | 0.89 | HPGD (0.44) | PPARGPPARAKMT2AHPGDSMN1; SMN2 | |
| SCHEMBL5136045 | 0.88 | PPARG (0.37) | PPARGPPARAMEN1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |